secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMERICA INC (BMRA)
CIK:        0000073290
Form:       8-K
Filed at:   2022-02-10T23:59:59+00:00
Accession:  0001513162-22-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomerica reports positive InFoods IBS endpoint trial results; multiple key endpoints show statistical significance
--------------------------------------------------------------------------------

- Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.
- Global Improvement Scale (GIS) endpoint p=0.040 for all patient subtypes (baseline vs 8 weeks).
- Abdominal Pain Intensity endpoint p=0.012 for IBS-Mixed & IBS-Constipation patients as a group.
- Bloating endpoint p=0.022 for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks).
- Company plans to meet with FDA to review results and finalize pivotal trial for FDA clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/73290/000151316222000014/0001513162-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/73290/000151316222000014/bmra-20220208.htm
  HTML page:      https://secwatch.observer/filing/0001513162-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer